Market Cap 39.29M
Revenue (ttm) 3.00M
Net Income (ttm) -20.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -680.00%
Debt to Equity Ratio -5.99
Volume 19,500
Avg Vol 39,362
Day's Range N/A - N/A
Shares Out 218.51M
Stochastic %K 66%
Beta 2.66
Analysts Strong Sell
Price Target $2.00

Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company's products are...

Industry: Health Information Services
Sector: Healthcare
Address:
2 Leman Street, London, United Kingdom
Latest News on RNLXY
No data available.